

Laryngeal oxygen concentration and apnoea time during microlaryngeal surgery using transnasal humidified rapid-insufflation ventilatory exchange (THRIVE) with different oxygen concentrations: A randomised controlled clinical trial

ACTRN12623000575639

Status RECRUITING
Sponsor Dr Liang Voice Program, The University of Sydney
Enrollment 102 participants

Plain Language Summary

When someone needs surgery on their voice box (larynx), surgeons need a clear view of the area without a breathing tube in the way. One technique called THRIVE (Transnasal Humidified Rapid-Insufflation Ventilatory Exchange) delivers oxygen through the nose at high flow, allowing surgeons to work without intubating the patient. However, using pure oxygen during laser surgery raises a fire risk. This study investigates whether using a lower oxygen concentration (30%) or no supplemental oxygen at all is safe and still keeps patients' oxygen levels adequate during the procedure.

Participants will be randomly assigned to receive either 30% oxygen via THRIVE or no supplemental oxygen (room air only) after an initial period of high-flow 100% oxygen. Oxygen levels, laryngeal oxygen concentration, and vital signs will be tracked throughout the operation.

You may be eligible if you are 18 or older and are scheduled for elective microlaryngeal surgery (surgery on the voice box). You would not be eligible if your resting oxygen levels are below 95%, you have a known lung condition such as COPD, or your BMI is above 31.

Key Eligibility Criteria

Inclusion (8)

- Age > 18 years
- Elective microlaryngeal surgeries, including but not limited to the following procedures:
 - Microlaryngoscopy with or without biopsy (MBS item number: 41855)
 - Microlaryngoscopy with removal of laryngeal lesion (MBS item number: 41861)
 - Microlaryngoscopy with removal of lesion including laser (MBS item number: 41861)
- ... and 3 more (see full listing online)

Exclusion (3)

- Baseline oxygen saturation level less than 95%
- Know history of lung disease, including but not limited to COPD and Type I or Type II respiratory failure.
- Body Mass Index (BMI) greater than 31.

Locations (1 total)

NSW, Australia

<https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=ACTRN12623000575639>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at anzctr.org.au. Generated by ClinicalTrialsFinder.org.